Avadel Pharma (AVDL) Misses Q2 EPS by 65c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2022 Financial Results
August 9, 2022 7:00 AM EDTReceived tentative approval for LUMRYZ (sodium oxybate) extended-release for oral suspension from FDA on July 18Advancing key activities to potentially accelerate final approval and shorten launch window of LUMRYZExtended cash runway to final FDA decisionManagement to host a conference call today at 8:00 a.m. ET
DUBLIN, Ireland, Aug. 09,... More
